Drug
Astagraf XL
Astagraf XL: highest development phase Post-Market, developed by Astellas. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Astellas
Trials
| Drug | Phase | Indication |
|---|---|---|
| Astagraf XL NCT02221583 | Post-Market | End Stage Renal Disease |
Latest
No recent events.
Follow Astagraf XL on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.